T40. Resveratrol Improves Cognitive Performance and Endothelial Function by Increasing BDNF Expression and Preventing Oxidative Stress During Experimental Vascular Dementia in Streptozotocin-Induced Diabetic Rats

Göçmez, Semil Selcen; Şahin, Tuğçe Demirtaş; Yazır, Yusufhan; Eraldemir, Fatma Ceyla; Polat, Selen; Utkan, Tijen

doi:10.1016/j.biopsych.2018.02.376

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herbal extracts have been proposed as an alternative medicine to delay the progression of AD, and some extracts have been shown to work through regulating BDNF. For example, resveratrol (3, 5, 4’-trihydroxy- trans -stilbene) treatment ameliorates oxidative stress and cognitive deficits in a rat model of vascular dementia by increasing hippocampal BDNF expression [ 307 ]. Chronic administration of curcumin, the main active ingredient in turmeric, alleviates AD-associated cognitive impairments via upregulating BDNF/ERK and Akt/GSK3β signaling in the hippocampus [ 308 – 311 ].…”

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

187

View full text Add to dashboard Cite

Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.

show abstract

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%